These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27098806)

  • 1. Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events.
    Egholm G; Thim T; Olesen KK; Madsen M; Sorensen HT; Jensen SE; Jensen LO; Botker HE; Kristensen SD; Maeng M
    Thromb Haemost; 2016 Jul; 116(1):172-80. PubMed ID: 27098806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
    J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.
    Basaraba JE; Barry AR
    J Cardiol; 2017 Jan; 69(1):353-358. PubMed ID: 27590413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials.
    Sawaya FJ; Morice MC; Spaziano M; Mehran R; Didier R; Roy A; Valgimigli M; Kim HS; Woo Park K; Hong MK; Kim BK; Jang Y; Feres F; Abizaid A; Costa RA; Colombo A; Chieffo A; Giustino G; Stone GW; Bhatt DL; Palmerini T; Gilard M
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):178-189. PubMed ID: 27426936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
    Faggioni M; Baber U; Sartori S; Giustino G; Cohen DJ; Henry TD; Farhan S; Ariti C; Dangas G; Gibson M; Giacoppo D; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2017 Apr; 10(7):645-654. PubMed ID: 28330641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.
    Palmerini T; Sangiorgi D; Valgimigli M; Biondi-Zoccai G; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Mariani A; Della Riva D; Genereux P; Leon MB; Bhatt DL; Bendetto U; Rapezzi C; Stone GW
    J Am Coll Cardiol; 2015 Mar; 65(11):1092-102. PubMed ID: 25790880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
    J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents.
    Smith BB; Warner MA; Warner NS; Hanson AC; Smith MM; Rihal CS; Gulati R; Bell MR; Nuttall GA
    Anesth Analg; 2019 Apr; 128(4):621-628. PubMed ID: 30169404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
    Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M
    Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
    Shah RR; Pillai A; Omar A; Zhao J; Arora V; Kapoor D; Poommipanit P
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):E99-E103. PubMed ID: 27184930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
    Abo-Salem E; Alsidawi S; Jamali H; Effat M; Helmy T
    Cardiovasc Ther; 2015 Oct; 33(5):253-63. PubMed ID: 26010419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
    Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.